1. Introduction

The JAK (Janus kinase)/STAT (signal transducers and activators of transcription) are members of a pathway implicated in the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) induced cytokine storm [1]. Classically, this functional aspect of the JAK/STAT pathway may be related to the cytokine receptor signaling. In unstimulated cells, the STAT proteins with SH2 domains are inactive and confined to the cytoplasm. Following cytokine receptor stimulation, STAT proteins bind to the phospho-tyrosine that contains sequences of the receptor, using SH2 domains [2]. Further, the JAK induced phosphorylation of STAT proteins at the cytokine type receptors causes subsequent dimerization of STAT proteins. The dimerization of STATs enables them to translocate inside the nucleus and stimulate apoptosis, immune regulation, cell cycle differentiation, and gene transcription as shown in Figure 1 [3].

Coronavirus disease 2019 (COVID-19), triggered by SARS-CoV-2 is a viral infection marked by respiratory illness, multiple organ failure, pneumonia, acute respiratory distress syndrome (ARDS), and ultimately death. Besides these symptoms, several systemic symptoms including lymphopenia, abnormalities of prothrombin time, ferritin levels, platelet count, acute partial thromboplastin time, and blood clotting anomalies have been seen in this disease [2]. While the upsurge in cytokine levels accounts for most of the inflammatory responses, it interrupts the apoptosis of endothelial cells that in turn affect vascular permeability, even though the signaling mechanisms accountable for the cytokine storm in COVID-19 are still unclear.

While the role of JAK/STAT signaling in COVID-19 has been suggested, nevertheless, the intricacy of these networks precludes a flawless understanding of the involvement of cytokine signaling in the COVID-19 pathophysiology. The objective of this review is to recapitulate current reports on the role of JAK/STAT signaling in COVID-19, focusing mainly on therapeutic strategies.

2. Stakeholders of SARS-CoV-2 mediated inflammation and its markers in COVID-19

Cytokines are molecular messengers released by the cells having specific actions on the interaction and communication between other cells [4]. They are formed from the critical role players of immunity and inflammation like natural killer (NK) cells, lymphocytes like T and B cells, dendritic cells, and the innate macrophages [5]. Cytokines consist of chemokines, interferons, interleukins, lymphokines, and Tumor Necrosis Factor (TNF) that mediate an essential role in regulating the
cell inflammation and corresponding immune responses. These constitute the essential messengers that control the signals that enhance or reduce the inflammatory actions to pathogens and any kind of stress or injury [6]. The pro-inflammatory cytokines like Interleukin-1 (IL-1), Tumor Necrosis Factor (TNF), Interleukin-6 (IL-6), and Interleukin-12 (IL-12) promote leukocyte activation. In contrast, anti-inflammatory cytokines like Interleukin 10 (IL-10), Interleukin-14 (IL-14), Tissue Growth Factor (TGF-β) suppress Phospholipase C (PLCs), and the chemokines like Interleukin-8 (IL-8) to recruit cells involved in inflammation [7]. Under normal conditions, cytokine response to infection is important [8]. However, with SARS-CoV-2 infection in the pneumocytes of alveoli, the resident alveolar macrophages, and the epithelial cells of the alveoli and damaged pneumocytes trigger an inflammatory response that releases cytokines and chemokines. This response further attracts more cells like natural killer cells, T-lymphocytes, bloodborne macrophages, and neutrophils which infiltrate from the blood into the alveoli and aggravate the inflammatory response as shown in Figure 2. Interestingly, STAT3 also is known to contribute to the cytokine storm via co-activation of IL-6 amplifier that enhances cytokine production [9]. The COVID-19 patients have been reported to present with high levels of pro-inflammatory cytokines like IL-6 and these levels have been attributed to the severity of the disease [10]. Additionally, GM-CSF, Interferon-γ (IFN-γ) mediated protein 10, TNF-α, monocyte chemoattractant protein 1, IL-2 R have also been identified in these patients [11]. Therefore, such aggravated conditions of hyper inflammation lead to a phenomenon called a cytokine storm that ultimately progresses towards ARDS and even death [12].

The SARS-CoV-2 uses the ACE2 receptor for accessing the host cells, especially the ones present on the Type II Pneumocytes. The spike protein consists of an S1 subunit that promotes attachment on the ACE2 receptor and an S2 subunit whose proteolytic cleavage is mediated by type II transmembrane serine protease (TMPRSS2), facilitates entry by membrane fusion. Upon entry of the virions in the host cells, they replicate, spread, and create inflammation in the lungs [13].

These inflammatory responses can lead to the release of macrophages, monocytes, and other cytokines and chemokines, leading to cytokine storms, thus deteriorating the conditions in COVID-19 patients [14]. Therefore, inflammatory markers play a crucial role in describing disease severity in COVID-19 patients. Recently, Zheng et.al described the role of markers of inflammation in COVID-19. They concluded that C-reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR), Procalcitonin (PCT), Serum Amyloid A (SAA), IL-6, and serum ferritin were elevated in severe COVID-19 patients compared to non-severe COVID-19 patients [15]. Similarly, along with the ability to release IL-6, SARS-CoV-2 infection is also capable of emancipating granulocyte-macrophage colony-stimulating factor (GM-CSF) from the T cells. The GM-CSF, in turn, can stimulate the inflammatory CD14+ and CD16+ monocytes, elevating IL-6 levels, and several other inflammatory mediators [16]. Apart from these, the COVID-19 patients are often reported to present with lymphopenia and neutrophilia, and
therefore, the Neutrophil-Lymphocyte Ratio (NLR) serves as the potential marker in these patients [17–19]. Feng et al demonstrated that severe conditions of COVID-19 present higher levels of NLR than COVID-19 cases of lesser severity. Thus, this significant increase in neutrophils and a decrease in lymphocyte could be an indicator of severity in COVID-19 progression [20].

2.1. Pneumocytes

The alveolar epithelium cells in the lungs express Type1 and Type 2 pneumocyte cells [21]. SARS-CoV-2 infects type 2 pneumocytes in the alveolar epithelium, abundant in ACE2 receptors, thus promoting effective binding onto the lung tissue [22,23]. Recently a study performed in cynomolgus macaques showed the distribution of SARS-CoV-2 in the type I and type II pneumocytes, the epithelial cells of nasal, bronchial, and bronchiolar mucosa lined with cilia exhibiting marked diffuse alveolar damage (DAD) [24]. The DAD is a peculiar feature observed in cases of ARDS where the patients suffer from the development of inflammation, hyaline membranes, injuries to the epithelial cells of the alveoli, bronchial edema, and even hemorrhage [25]. Recent studies have reported DAD in COVID-19 patients [26,27]. Apart from the known ACE2 receptors, Scott et al demonstrated the ability of a novel receptor CD209L also termed as L-SIGN, to be a potential receptor for SARS-CoV (severe acute respiratory syndrome coronavirus) entry into the host, and synergistically, these receptors were expressed in human alveolar cells type II and endothelial cells of the lungs [28].

Interestingly, another study showed that novel progenitor CD 34+ Oct 4+ cells through L-SIGN facilitated entry of the virus into cytokeratin” respiratory epithelium could result in cytopathy and inflammation [29]. These cells also possess high levels of ACE2 receptors and therefore share a possibility of getting infected by SARS-CoV. Other stem cells present in the respiratory tract include club cells, bronchioalveolar stem cells, basal cells, along with type II pneumocytes that also contain ACE2 receptors [30].

An interesting recent report describes the correlation between ACE2 receptor distribution and Interferon stimulated gene (ISG)/IFN signaling in the basal cells of nasal epithelium via the JAK/STAT pathway. Upon the release of IFN-α2 and IFN-γ, the levels of STAT1 are enhanced leading to upregulation of the ACE2 receptors promoting binding of SARS-CoV-2 in the host [31].

2.2. Endothelial cells

During the early course of infection, endothelial cells are infected [23]. It has high ACE2 expression through which SARS-CoV-2 gain access to enter the host cell. They also constitute CD147 (Extracellular matrix metalloproteinase inducer), TMPRSS2, and sialic acid receptor [32]. They undergo viral replication and apoptosis via Fas/FasL or TRAIL-PR-5 dependent mechanisms. SARS-CoV resulted in endothelial cell dysfunction leading to microcirculation disorder [23].

Infected bronchial epithelium in COVID-19 patient was studied to manifest a strong relation of SARS-CoV with SARS-CoV-2 in immunological pathophysiology and pro-inflammatory cytokines which lead to cytokine storm in affected COVID-19 patients [33]. Endothelial activation in Cytokine Storm Syndrome (CSS) may lead to unstable hemodynamics, capillary leakage, and coagulopathies and
increased production of pro-inflammatory cytokines could release von Willebrand factor and angiopoietin-2 that further stimulate the endothelium activation [34]. The release of cytokines following a SARS-CoV-2 infection was seen to activate the JAK/STAT pathway in the cells of pulmonary endothelia [35].

2.3. Macrophages and monocytes

Macrophages are the first-line defense against viral infections and a potent source of inflammatory cytokines. Monocyte and macrophage are rich in ACE2 receptors that cause activation and transcription of pro-inflammatory genes [36]. Several laboratory mice strains are unable to support ACE2 binding studies and therefore effort is made to incorporate human ACE2 into mice out of which one such model is the K18-hACE2-transgenic mice [37]. Interestingly, reports have demonstrated the significant pathogenic potential of SARS-CoV-2 when evaluated in hACE2 transgenic mice [38,39]. Upon SARS-CoV-2 infection in K18 type of hACE2 (K18-hACE2) transgenic mice, high amounts of viral RNA was detected in the lungs accompanied by increased levels of pro-inflammatory cytokines, chemokines, monocytes, neutrophils along with T cells leading to a pneumonia-causing collapse in alveolar cavities [40].

Evidence from COVID-19 patients has demonstrated that CD169+ macrophages rich in ACE2 are present in spleen and lymph nodes [40]. These macrophages were shown to upregulate IL-6 and possess the SARS-CoV-2 nucleoprotein antigen. Other virus-infected tissues also showed an increase in levels of CD95 (Fas), thus suggesting that CD169+ macrophages could promote viral infectivity, inflammation, and lymphocytic necrosis [41].

The low molecular weight fraction of human serum albumin (LMWFS5A) can prevent hyper inflammation, development of cytokine storm, and promote vascular permeability [42]. They have shown an immunomodulatory action causing a shift in M1 inflammatory macrophage to M2 anti-inflammatory macrophage as evident in an in-vitro study [43].

COVID-19 patients produce IL-6, IL-10, and TNF along with CD11b, CD14, CD16, CD68, CD163, and CD206 [7]. A higher expression of cytokines was associated with them with HLS. FCN1+ (High inflammatory derived ficolin-1) macrophages as found in the autopsy reports of bronchoalveolar lavage fluid (BALF) in ARDS diagnosed COVID-19 patients [44]. STAT 1, STAT 2, and several regulatory factors relating to IFN were activated by Monocyte-derived macrophages [45]. Thus, ill-regulated inflammatory response and T cell apoptosis can expedite activation and accumulation of inflammatory monocyte/macrophage [7].

2.4. Lymphocytes

T lymphocyte, CD4+T, and CD8+T play a prominent role in developing autoimmunity and inflammation [45]. Critically ill patients in COVID-19 had a marked decrease in T and B cells [7]. Nevertheless, CD4+T and CD8+T play a vital part in the elimination of coronaviruses from the infected cell by inducing immune lesions [45,46]. Helper T cells (Th1) through the NF-kB signaling pathway produce pro-inflammatory conditions that result in further activation of cytokine and chemokine cascades [46]. About 85% of COVID-19 patients revealed peripheral blood lymphopenia and unexpected infiltration in the airways due to the dysfunction of innate T cells against SARS-CoV-2 [45]. IL-6 can suppress T cell activation, causing lymphopenia [23]. Levels in COVID-19 patients confirmed a downstream indicator of cell pyroptosis which is suggested as a cause of lymphopenia [23]. Regulatory T cells (Treg) were upregulated in severe cases; reduced/unchanged in some cases playing a central role in balancing antiviral immunity and cytokine storm [7]. Laboratory reports of severe COVID-19 patients exhibited decreased B cell levels as compared to mild infection [47].

The antiviral role of CD4+ and CD8 + T cells is significant in combating pathogens. T-dependent B cell activation by CD4 + T cells promotes virus-specific antibodies. Virus-infected cells can be destroyed by cytotoxic CD8 + T cells [48]. In patients infected with SARS-CoV, the pulmonary interstitial cells accounts for, by CD8 + T cells, have 80% of total inflammatory cells which are infiltrated which is vital for the clearance of coronaviruses from infected cells, thereby resulting in an injured immune system. While the viral replication is not affected or delayed as a result of CD8+ depletion during the SARS-CoV infection, the depletion of CD4 + T cell is responsible for the reduction in the neutralizing antibody, pulmonary recruitment of lymphocytes, and cytokine production causing delayed SARS-CoV clearance from lungs and immune-mediated interstitial pneumonitis, etc [48]. While the inhibition of serum containing proteins leads to control of the complement system, it also damages the host tissue. As the viral proteins manage to evade complement system detection, it highlights the significance of the complement system in antiviral activity [49]. The differentiation, growth, and survival of T cells especially the CD8+ and the CD4 + T cells is mediated via STAT 3. STAT 3 facilitated stimulation of CD8 + T cells during a viral attack provides a strong immune response against the virus [50].

2.5 Natural Killer (NK) Cells and Dendritic Cells

In peripheral tissues and circulation, NK cells are present. NK cells do not reside permanently in tissue and dynamically move between blood and tissues. Thus, during a viral invasion like SARS-CoV-2, sensing the chemokine gradient, NK cells are recruited to the area of infection [44]. In COVID-19 patients, in peripheral blood, there was an increase in the myeloid cells, but the NK cells were found to be decreased [51]. However, it is presumed that the virally infected cells express specific putative ligands to activate the NK cell receptors to trigger NK cell killing [52]. Through their corresponding ligands, the natural receptors of cytoxotoxins such as NKP30, NKP44, NKP46, C-type lectin-like receptors NKG2D and Nkp80 (KLRF1) and co-activation receptors as DNAM-1 may get activated in NK cells [52].

In severe cases of COVID-19, the peripheral bloodstream had lesser NK cells. NK cell destroys virus incorporated cells by degranulation, cell apoptosis mediated by receptors, and antibody-dependent cell-facilitated cytotoxicity. There were no
significant differences in mild v/s severe cases, in the number of CD16+, and CD56+. Anyhow, further studies would be needed to determine the contribution of these cells in cytokine release [7].

Dendritic cells help to release pro-inflammatory mediators like TNFα and aid inactivation of T lymphocytes [46,53]. The exact mechanism of dendritic cells in SARS-CoV-2 is not known. IL-6 from dendritic cells binds to IL-6-R/sIL-6-R gp-130 (soluble IL-6 Receptor glycoprotein 130) and activates the JAK/STAT pathway, which can lead to vascular permeability, monocyte recruitment, neutrophil recruitment, and signal amplification [32]. The SARS-CoV-2 infection was also shown to turn down the IFN cascade in the monocyte-derived dendritic cells by preventing the phosphorylation of STAT1 [54]. In the NK cells, the IL-15 mediated by JAK1 regulates their development, growth, and functioning. Similarly, IL-2 signals from JAK1,3 and STAT1,3,5 enhance the cytotoxicity of NK cells [55].

Therefore, a summary of all the above-mentioned stakeholders of inflammation involved in the development and maintenance of the cytokine storm in COVID-19 is given in Table 1.

3. Role of JAK/STAT signaling pathway in the immune system

The JAK/STAT signaling pathway can influence the immune system functioning to a significant extent. The JAK/STAT signaling components like JAK1-3 and STAT1-6 have been associated with various roles in immune responses like IL-2, IL-4, IL-6, IL-12 signaling, Th (T-helper), Th2, Treg cell and Th9, Th 17 cell differentiation, the proliferation of viral selective CD8+ T cells and B-cell lymphoma 2 (Bcl-2) [2,56]. It is evident that cytokines are necessary for combating viral infections but the hyperinflammatory conditions created by SARS-CoV-2 infection due to cytokine storm could lead to conditions like ARDS and even death [9]. To prevent this, the inhibition of the JAK/STAT pathway may look to be a promising strategy but having said that, prolonged inhibition of this pathway could lead to compromised immune responses in the body that could promote the proliferation of the SARS-CoV-2. The viral infection could also further promote inhibition of inflammatory signaling pathways causing immunosuppression [57]. Recently, Bouwman and colleagues reported that JAK/STAT signaling system could be a valuable indicator of a strong immune response to SARS-CoV-2 infections [58]. Interestingly, another report stated that the inhibition of the JAK/STAT pathway could reduce the hyperinflammatory conditions but not the viral clearance [59]. This could suggest that COVID-19 patients who are immunocompromised could be susceptible to superinfection via inhibition of the JAK/STAT pathway that would call for cautionary use of JAK/STAT inhibitors.

4. Deciphering the link between SARS-CoV-2 proteins and JAK/STAT Signaling

SARS-CoV-2 is a member of β-coronavirus genera in the Coronaviridae family that shares about 96.7% sequence similarities with the bat strain RaTG13 and the pangolin isolates [13,60]. It contains a single strand of a positive-sense RNA genome with 29,903 base pairs [61]. The viral RNA is enclosed in an enveloped structure and when viewed under an electron microscope, appears as a crown-like structure due to the incorporation of structural spike proteins on its outer surface that facilitates its entry, proliferation, and infectivity in host cells via ACE2 receptors [62,63]. The ACE2 receptors are expressed in epithelial cells of the kidney, heart lungs, and

| Table 1. Summary of stakeholders in the development of cytokine storm in COVID-19. |
|-----------------------------------------------|
| **Type of Cells** | **Description** |
| **Pneumocytes** | - SARS-CoV-2 bind Type 2 pneumocytes rich in ACE2 receptors  
- SARS-CoV-2 infected pneumocytes show diffused alveolar damage, a peculiar feature in COVID-19 patients diagnosed with ARDS.  
- Alveolar cells express L-SIGN (CD209L), a novel receptor for SARS-CoV binding.  
- Presence of ACE2 receptors on novel progenitor CD 34+ Oct 4+ cells could also enhance viral binding.  
- IFN mediated stimulation of STAT1 could upregulate ACE2 receptor levels in nasal epithelium. |
| **Endothelial Cells** | - The presence of ACE2 receptors along with CD147, TMPRSS2, and sialic acid receptors facilitate SARS-CoV-2 binding and penetration.  
- Viral infectivity occurs via Fas/FasL or TRAIL-PR-5 mediated mechanisms.  
- Cytokine storm induced by the uncontrolled release of pro-inflammatory cytokines can release von Willebrand factor and angiopoietin-2 that further stimulate the endothelium activation.  
- Activation of JAK/STAT signaling follows upon cytokine release. |
| **Macrophages and Monocytes** | - Both rich in ACE2 receptors  
- Transfection of SARS-CoV-2 onto ACE2 receptors of K18-hACE2-transgenic mice macrophages showed significant infectivity.  
- CD169+ macrophages rich in ACE2 receptors possess SARS-CoV-2 nucleoprotein antigen and stimulate IL-6 levels.  
- High levels of HIF,FCN1+ was found in bronchoalveolar lavage fluid of COVID-19 diagnosed with ARDS.  
- Monocyte-derived macrophages activate STAT1, STAT2, and IFN regulatory factors. |
| **Lymphocytes** | - T lymphocyte, CD4+ T, and CD8+ T develop autoimmunity and inflammation.  
- T cell and B cell levels in COVID-19 patients are decreased.  
- CD4+ T and CD8+ cells eliminate viral particles via immune lesions.  
- IL-6 and IL-1β lead to lymphopenia in COVID-19 patients.  
- STAT3 mediated CD8+ T cell stimulation provides a greater immune response against SARS-CoV-2. |
| **NK cells and Dendritic cells** | - NK cell reduction is evident in SARS-CoV-2 infection.  
- Viral cells mediate NK cell destruction.  
- NK cells neutralize SARS-COV-2 via degranulation, apoptosis, and cytotoxicity.  
- Dendritic cells release IL-6 that activates the JAK/STAT pathway to combat SARS-CoV-2.  
- The prevention of STAT1 phosphorylation by SARS-CoV-2 in dendritic cells reduces IFN signaling.  
- JAK/STAT signaling plays an essential role in the development and functioning of NK cells. |
blood vessel endothelial cells. They are also expressed on monocyte and macrophages [36]. Differentiated enterocytes, lymph nodes, and spleen macrophages like CD68+ and CD169+ also express ACE2 receptors [7]. In the CNS, ACE2 is expressed in the glial cells and cell bodies of neurons [64,65]. Another manifestation of SARS-CoV-2 infection is the development of diarrhea in infected patients that suggest the expression of these receptors in the gastrointestinal (GI) system [66].

The genome comprises of 10 Open Reading Frames (ORFs), out of which ORF1a/b encodes for polyprotein 1a (pp1a), polyprotein 1b (pp1b), and 16 nonstructural proteins (nsp). The residual ORFs encode for structural proteins like Spike, Nucleocapsid, Envelope, and Membrane protein abbreviated as S, N, E, and M [67,68]. The pp1a and pp1b are transformed into two proteases namely 3CLpro (3 chymotrypsin-like proteases) and PLpro (papain-like protease). The PLpro facilitates cleaving of nsp1, nsp2, and nsp3 while 3CLpro is responsible for the processing of nsp4- nsp16 [69]. The nsp5 especially play a crucial role in the development of the replicase complex that is required for genome transcription and virus replication [70].

Among the several nsp's of SARS-CoV-2, the nsp1, nsp3, nsp 6, nsp13, inhibits STAT1 dependent expression of ISGs by suppressing the STAT1 phosphorylation and reducing inflammatory conditions. Amongst the ORF, ORF3a and ORF 7b inhibit STAT1. The nsp6 and nsp13 also inhibit STAT2 phosphorylation along with ORF 7a and ORF 7b [71–73]. It is also reported that ORF 6 could inhibit nuclear transportation of STAT1 via binding to karyopherin -α2 [73]. The SARS-CoV-2 3CLpro enzymatically causes a reduction in STAT1 protein levels and STAT1 induced IFN phosphorylation and hampers STAT1 nuclear translocation. It is also suggested that 3CLpro could promote autophagic degradation of STAT1. In conditions where 3CLpro was seen to be expressed in high amounts, the viral replication was enhanced due to the reduction in IFN and ISG signaling pathways [74]. The PLpro also houses de-ubiquitination and de- ISGylation properties via the JAK-STAT pathway. Specifically, it is known to cleave STAT2 and affect the interferon signaling [31,75]. Among the structural proteins of SARS-CoV-2, the N protein has also been shown to inhibit the type 1 IFN pathway mediated inflammatory cascade by preventing the phosphorylation and nuclear passage of STAT 1 and STAT 2 as shown in Figure 3 [76].

Besides hyper inflammation, coagulopathy also contributes to the severity of the condition. Thus, modulation of monocyte and endothelial cell activation via Oxidized Phospholipids (OxPLs) produced on oxidative stress were studied to avert thrombotic complications in those with

**Figure 3.** Interaction of SARS-CoV-2 proteins with JAK/STAT signaling.
cardiovascular and other metabolic comorbidities [77]. From the studies conducted, various strategies that block ACE2 receptor; TMPRSS2 inhibitors like Camostat mesylate; anti-IFN-γ drugs like Emapalumab that target STAT1; JAK1 and JAK2 inhibitors like Baricitinib, Ruxolitinib that inhibit ACE2 mediated endocytosis; monoclonal antibody targeting S protein; PARPs intervening antiviral ADP-ribosylation can aid in the treatment of this disease [47,60,78].

5. Modulating JAK/STAT signaling pathway in COVID-19

Various regulatory agencies now uphold JAK inhibitors (JAKinibs) for the treatment of immune-mediated diseases [79]. Aberrant activation of STAT3 is a characteristic feature of abnormal cellular differentiation and proliferation [80]. The FERM and SH2 like domains of JAKs regulate the kinase activity, whereas gene transcription is modulated by STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6 [81]. The inhibitory mechanism of the SOCS (Suppressors of Cytokine Signalling) protein family or autoinhibition of JH1-JH2 interactions are few driving techniques in controlling the anomalous activation of the pathway [81,82]. SOCS proteins induced downregulation of the pathway is either by the direct disruption of JAK phosphorylation or by its proteasomal degradation [83]. Even so, a negative feedback loop is formed where transcription of SOCS1 to SOCS7 and Cytokine Inducible SH2 containing protein (CIS) is upregulated by the STATs [82]. Moreover, STAT1 stimulation causes hyperactivation of pro-inflammatory molecules like COX2 promoting immune suppression, cancer persistence, and drug resistance to doxorubicin, cisplatin, docetaxel [84]. Studies suggest that phosphorylation of Activation loop (AL) of JH1 can intramolecularly regulate JAK Tyrosine Kinase activity [82]. Another mechanism of regulation includes the dephosphorylation of activated JAKs and STATs by multiple Protein Tyrosine Phosphatase (PTP) including SHP1; SHP2 (both activator and suppressor) and TC-PTP for STAT1, STAT3, STAT5; PTPRT for STAT3; CD45 for JAKs [82,83]. Intermolecular regulation is mostly involved in the termination of signaling after cytokine stimulation [82]. Also, termination of the pathway is initiated by various inhibitory residues causing dissociation of JH2 from a receptor, strengthening JH1-JH2 inhibitory interactions, production of inhibitor proteins, and removal of signaling complexes through internalization. Upon the evidence, inhibition of activated STAT dimers by Protein Inhibitors of Activated STATs (PIAS) namely PIAS1, PIAS2 (PIASx), PIAS3, PIAS4 (PIASy) also are crucial in modulating JAK/STAT signaling [82,83].

6. JAK/STAT inhibitors as therapeutic agents against COVID-19

The role of cytokines in COVID-19 has been a contributor to the worsening of the disease and inhibiting these cytokines to reduce inflammation has been a strategy to keep the disease under check. The cytokines via the cytokine receptors are known to activate the JAK/STAT cascade [85]. Evidence states that activation of the JAK/STAT pathway mainly via cytokines like IL-6 is correlated with subsequent aggravation of COVID-19 [86]. Therefore, a significant focus has shifted towards the development of JAK inhibitors as a therapeutic aid in COVID-19. Interestingly, TH 17 signaling has shown to lead towards cytokine storm in COVID-19 patients causing damage to tissues and pulmonary edema [87]. IL-6 and IL-23 signaling facilitated by STAT-3 is essential in maintaining cell differentiation of Th17 cells and its effector functions [88]. In turn, the IL-6 and IL-23 activate STAT-3 via JAK-2 and thus JAK2 inhibitors could prevent the inflammatory cascade [89]. Similarly, SOCS include members namely SOCS1- SOCS7 and CIS. They inhibit JAK/STAT signals either by JAK kinase activity inhibition or the prevention of STAT binding to JAK [90]. The ability of SOCS to inhibit JAK kinase is supported by the kinase inhibitory region (KIR) in SOCS [83]. Within the SOCS family, SOCS1 is regarded as the most important and highly potent inhibitor of JAK1 and JAK2. This could be possibly due to the use of both KIR and SH2 binding domains by SOCS1 in inhibiting JAK kinase [91]. Along with SOCS, another set of specific proteins namely PIAS also negatively regulates the JAK/STAT pathway. The PIAS family mainly contains PIASx, PIASxα, PIASxβ, PIAS3, PIASy [92]. They could prevent the transcription by hindering the transcription factor’s DNA-binding process, enhancing co-regulators like histone deacetylases to repress transcription, and promoting the transcription factor’s SUMOylation process where SUMO refers to Small Ubiquitin-like Modifier [93]. The PTPs are also involved in inhibiting the JAK/STAT pathways. Their extensive family includes protein encoded by genes namely Protein Tyrosine Phosphatase Non-Receptor (PTPN) Type 1, PTPN Type 2 (PTPN2), PTPN Type 6 (PTPN6), PTPN Type 11 (PTPN11), Dual Specificity Phosphatase 3 (DUSP3), and Protein Tyrosine Phosphatase Receptor Type C (PTPDC) [93]. They are mainly known to dephosphorylate JAK/STAT proteins. The PTPs like Src homology region 2 domain-containing phosphatase-2 (SHP-2) also known as PTPN11 mainly dephosphorylate nuclear STAT1 and cytoplasmic STAT5. The T cell PTP (TC-PTP) dephosphorylates STAT1 and STAT3 [94]. The TC-PTP is cytosolic phosphatases that also inhibits the JAK/STAT signaling through the dephosphorylation of JAK/STAT proteins [95]. Similarly, the Protein Tyrosine Phosphatase 1B (PTP1B) formed from the PTPN1 gene promotes STAT1 and STAT3 dephosphorylation thus affecting the JAK/STAT pathway [96].

Thus, the role of SOCS, CIS, PIAS, and PTP is crucial in regulating the JAK/STAT pathway as depicted in Figure 4.

Therefore, even though it appears simple that the JAK/STAT signaling is influenced by a wide variety of proteins, the exact mechanism of action occurring at molecular levels is still foggy to draw concrete conclusions of the same. Having said that, employing the evidence of enormous current knowledge about these JAK/STAT inhibitors further detailed investigations are necessary.

6.1 Ruxolitinib

Ruxolitinib, an orally bioavailable JAK inhibitor with European Union approval is preferred to treat primary myelofibrosis (PMF) that hampers normal blood cell formation capabilities, post essential thrombocytopenia myelofibrosis (PET-MF) or
post polycythemia vera myelofibrosis (PPV-MF) [97]. It inhibits JAK 1 and JAK 2 by terminating the kinase activity, thereby preventing STAT activation and nuclear translocation. Ruxolitinib induced inhibition of the IL-6/JAK/STAT3 pathway could cause a significant reduction of IL-6 levels [98]. It can overcome complications due to immune hyperactivation by the JAK/STAT signal transduction pathway and potentially knockdown the hyper inflammation reducing the lung impairment and restoring the PaO2/FiO2 ratio in COVID-19 patients [99].

Ruxolitinib is used to treat severe COVID-19 disease associated with ARDS by inhibition of cytokine signaling [100]. Numerous clinical trials are underway to evaluate the role of Ruxolitinib in COVID-19 patients.

A multi-centered phase II clinical trial (NCT04348071) employing Ruxolitinib in COVID-19 patients characterized by CSS was proved to be safe and efficacious in the intervention and prevented multi-organ failure. Similarly, Incyte and Novartis have initiated a phase III trial for Ruxolitinib (NCT04362137), evaluating the effectiveness of Ruxolitinib in severe COVID-19 patients having respiratory disorders. Table 1 enlists the registered clinical trials employing Ruxolitinib to treat COVID-19 patients.

**6.2 Baricitinib**

Baricitinib is a kinase inhibitor that competes with ATP (adenosine triphosphate) to effect effectively and reversibly inhibit both JAK1 and JAK2 with high selectivity hindering the pro-inflammatory signals of several cytokines like IL-6, IL-12, IL-23, etc., intracellularly [101]. Recently a pilot study done by Cantini et.al showed that Baricitinib possesses good safety and efficacy profiles in COVID-19 patients showing no side effects [102].

Baricitinib is evident to be the safer approach in patients with moderate COVID-19 inhibiting release of cytokines as an anti-inflammatory agent and endocytosis of SARS-CoV-2 virions [103]. It also plays a vital role in blocking proteins of the host cell responsible for the viral reproduction, and being an anti-inflammatory agent, also reduces the inflammation in ARDS patients as well [101].

Recently, phase III clinical trials were initiated by Eli Lilly employing Baricitinib (NCT04421027) to analyze its safety and effectiveness. It is a randomized interventional trial with nearly 600 participants, possessing at least one elevated inflammatory marker but without the requirement of medical ventilation. Lilly expects a reduction of cytokine storms associated with the virus through Baricitinib treatments. A regime including Baricitinib 4 mg daily with background therapy or placebo with background therapy was received by the patients for up to 14 days.

Likewise, several on-going studies are to be progressed with Baricitinib. A report by Bronte et.al stated that it aids to amend the immune abnormalities in COVID-19 hospitalized patients [104]. Another phase III clinical trial evaluates the role of Baricitinib + Remdesivir combination (NCT04401579) for the treatment of COVID-19. It is an interventional randomized study aimed to primarily assess the recovery time of
COVID-19 patients taking a combination of Baricitinib + Remdesivir as compared to patients taking only Remdesivir.

6.3 Tofacitinib

Tofacitinib is frequently indicated in rheumatoid arthritis (RA), colitis, and spondylitis owing to its anti-rheumatic effects [105]. It inhibits mainly JAK1 and JAK 3 and to a lesser range the JAK2 and TYK 2. The inhibition of JAK, especially JAK1 and JAK3 blocks the signaling of multiple interleukins as shown in Figure 4, thus reducing inflammatory cascade [106].

With such an effective role as a JAK inhibitor, clinical trial investigations on Tofacitinib are now targeted for COVID-19. Although clinical trials are undergoing in different parts of the world, the studies are bounded in contrast to other JAK inhibitors. Nevertheless, it is currently undergoing phase II trials through Investigator-Initiated Studies (IIS) in which everyone enrolled in the trial has received experimental therapy. Pfizer mainly intended on how safe and efficacious Tofacitinib was, in COVID-19 patients (NCT04469114), that were hospitalized on account of pneumonia and received standard of care therapy. It is designed as a multi-centric study, that is randomized and double-blinded, having a placebo-control employing 260 participants.

A study developed by Yale University focuses on the safety and even the efficacy potential of Tofacitinib for moderate COVID-19 patients (NCT04415151). It is also a randomized study, with double-blinding and placebo-control at the phase II stage with 60 participants. It is carried out in COVID-19 patients having pneumonia, requiring supplemental oxygen and serological markers of inflammation but not mechanical ventilation. This study primarily establishes whether tofacitinib improves the clinical outcomes in patients with moderate SARS-CoV-2 infection.

Therefore, a summary of these inhibitors used in COVID-19 having actions on their respective cytokine receptors is shown in Figure 5.

6.4 Other drugs modulating the JAK-STAT pathway in COVID-19

Other multiple ways to modulate the functioning of the JAK-STAT signaling also have paved the way out. One such method is using oligodeoxynucleotide (ODN) decoys that inhibit the DNA binding domains and inhibit gene expression [107]. Anti-sense oligonucleotides have also been used to interact with STAT3 signaling in cancer cells [108]. Like the above mentioned JAK inhibitors, Fedratinib, an FDA approved JAK2 inhibitor also has shown potential in providing relief to COVID-19 patients. Through the IL-6 and IL-23 signaling, STAT 3 facilitates the differentiation of T Helper 17 (TH17) cells. Both these interleukins promote STAT3 activation via JAK2 and therefore the JAK2 inhibitors could prevent the inflammatory actions of TH17 cells thus reducing inflammation in COVID-19 patients [87]. While the JAK inhibition may hamper the activity of the inflammatory signaling in the host, combination therapies of JAK inhibitors along with antivirals like remdesivir/lopinavir/ritonavir could be helpful in controlling inflammation in COVID-19 cases. This could prevent unwanted inflammatory consequences in the host.

Figure 5. Some of the JAK/STAT inhibitors used in COVID-19.
and provide an effective way to reduce viral infectivity and spread [1]. Interestingly the JAK-STAT pathway is also activated by the IL-6 [3]. The IL-6 is produced by the binding of Angiotensin II to the type 1 Angiotensin II receptor (AT1 receptor) through JAK/STAT initiation [109]. The SARS-CoV-2 S protein serves as a down regulator of ACE2 ultimately causing overexpression of angiotensin II thus in-turn increasing IL-6 production.

Therefore it could be concluded that drugs like tocilizumab and Sarilumab that inhibit IL-6 could prove effective in the management of inflammation in COVID-19 patients.

7. Possible side effects of drugs altering the JAK-STAT signaling in COVID-19

The use of Ruxolitinib has shown side-effects like purpuric lesions on the skin of limbs and erythromed rash in 2 SARS-CoV-2 patients. Anemia was also diagnosed in many studies and trials, increase the risk for opportunistic infections [110]. Whereas common side effects include myelosuppression, GI toxicity, immunosuppression, bladder pain, dizziness, headache, sore throat, skin rashes, weight gain, flatulence, etc [111].

The side effects like headache, upper respiratory tract infection (UTI), nasopharyngitis are commonly seen in patients with Baricitinib therapy. The long term use of Baricitinib may increase the risks of developing serious infections and thromboembolic events in patients [112]. Consumption of Immunosuppressants concomitantly with Baricitinib was more likely prone to these infections. Other side effects include fungal infections (candidiasis), pneumocystis, bacterial, viral infections, pneumonia, Herpes zoster, UTI, acute hstore, cryptococcosis, etc [101].

Elevation in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Anemia (Hb<8 g/dl), neutropenia, lipid level elevation (increased TC, LDL, HDL), GI perforation, malignancy, and lymphoproliferative disorders were reported [113].

Tofacitinib also exhibited side effects like abdominal pain, acne vulgaris, anemia, angioedema, diarrhea, dehydration, dyspepsia, headache, hepatotoxicity, hyperlipidemia, hepatitis, lymphoma, lymphopenia, nausea, neutropenia, pulmonary embolism, rashes, vomiting, blood clots, GI perforations [113].

8. Regulatory authorities’ verdict on the usage of JAK Inhibitors against COVID-19

WHO declared the outbreak of the COVID-19 as pandemic on February 11th, 2020, which to date has exceeded 34 million confirmed cases with greater than 10 lakhs deaths across the world [114,115]. The International Solidarity trial was launched by WHO to compare agents that could prove effective against COVID-19 and discover effective drugs to slow disease progression or improve survival in COVID-19 patients [116]. US FDA and European Medicine Association have approved JAK inhibitors like Ruxolitinib, Baricitinib, Tofacitinib, Fedratinib, Oclacitinib, Upadacitinib [86]. Four effective strategies established by FDA in repurposing already approved agents include priority screening of agents, selection of therapies that have attained breakthroughs, accelerating the approval, and applying fast track to selective processes. The Indian Council of Medical Research (ICMR) collaborated with the Australian authorities for expediting attainment and approvals [117]. National Institute of Health (NIH), has conducted various studies on these agents to frame treatment guidelines. Baricitinib, selective JAK1, and JAK2 inhibitor is postulated to inhibit AP2 associated protein kinase 1 (AAK 1), which regulates endocytosis in alveolar type 2 (AT2) epithelial cells in the lungs and has the greatest theoretical antiviral efficacy [118]. National Institute of Allergy and Infectious Diseases (NIAD) has developed a clinical trial undergoing phase III to test the efficacious nature of Baricitinib (NCT04401579) with antiviral Remdesivir in COVID-19 patients in the US with nearly 1034 participants. It is a randomized study, that is double-blinded having placebo-control which evaluates the putative benefit of Baricitinib. An independent Data and Safety Monitoring Board (DSMD) concluded that the study showed positive results with improved recovery time over Remdesivir alone. Besides, another trial justified that Ruxolitinib in addition to standard of care (SOC) treatment mitigated exuberant cytokine storm associated with COVID-19 [100]. To date, no specific drug or vaccine is recommended by WHO to prevent or cure COVID-19, but the efforts in the development of the therapeutic strategies are still ongoing.

9. Current status of clinical trials

Currently, a total of 40 studies have been enlisted under clinicaltrials.gov that involve the use of JAK inhibitors like Ruxolitinib, Baricitinib, Tofacitinib, and Pacritinib for COVID-19 either as a single or a combined regimen with other drugs. Out of these 40 studies, 20 trials are related to Ruxolitinib, 15 trials to Baricitinib, 4 trials to Tofacitinib, and 1 trial to Pacritinib. In general, 14 studies have not started recruiting subjects while 21 studies are already recruiting subjects, the subjects for 2 studies are available. Amongst these studies 1 is completed and 2 are withdrawn.

Among 20 studies of Ruxolitinib, 1 study was withdrawn (NCT04354714) as the changes suggested by the FDA could not be made. Out of the 19 studies, two were expanded access type (NCT04337359) and (NCT04355793). The remaining 17 studies included mainly interventional studies and few observational studies with Ruxolitinib as a single regimen and in combination with other drugs as shown in Table 2.

Out of 14 Baricitinib studies, 1 was completed (NCT04358614) and 13 were active. Out of the 13, 10 were of interventional design and 3 were observational. Most of the studies were having Baricitinib as the sole regimen while a few studies employed combinations of Baricitinib with other drugs as mentioned in Table 3.

Out of 5 studies of Tofacitinib, 1 study (NCT04412252) is withdrawn due to other SARS-CoV-2-related research including alternative trials with tofacitinib. Mostly all the studies
Table 2. Summary of active clinical trials employing Ruxolitinib in COVID-19 patients.

| Clinical Trials Identifier | Study Parameters | Intervention groups | Outcomes |
|----------------------------|------------------|---------------------|----------|
| NCT04348071               | • Single-arm     | • Ruxolitinib       | • Cumulative events affecting daily living, clinical status, and life-threatening events. |
|                           | • Open-label     | Ruxolitinib 10 mg- orally twice daily |
|                           | • Single site    |                     |          |
|                           | • Interventional |                     |          |
|                           | • n = 80         |                     |          |
| NCT04377620               | • Randomized     | • Ruxolitinib       | • Participants dead due to non-specific reasons |
|                           | • Double-blinded | Ruxolitinib 5 mg + SOC – BID 12 hours apart orally or enterically |
|                           | • Placebo-controlled | Ruxolitinib 15 mg + SOC – BID 12 hours apart orally or enterically |
|                           | • Multicentered  |                     |          |
|                           | • Interventional |                     |          |
|                           | • n = 500        | Placebo             |          |
| NCT04414098               | • Experimental   | • Placebo + SOC – BID 12 hours apart orally or enterically. | • Evaluation of Ruxolitinib efficiency in COVID-19 treatment |
|                           | • Open-label     | Ruxolitinib- 5 mg/12 hours up to 14 days and taken orally. |          |
|                           | • Prospective    |                     |          |
|                           | • Single centered |                     |          |
|                           | • Add-on         |                     |          |
|                           | • Interventional |                     |          |
|                           | • n = 100        |                     |          |
| NCT04366232               | • Randomized     | • Anakinra          | • Measurement of: |
|                           | • Open-label     | Anakinra- 300 mg, 1/day Intravenous (I.V) route lasting for 5 days and subsequently tapering of dose. | C-Reactive Protein (CRP) Ferritinemia, Serum creatinine, AST/ALT, Eosinophils |
|                           | • Parallel assignment |                     |          |
|                           | • Interventional | • Anakinra + Ruxolitinib |          |
|                           | • n = 54         | Anakinra-300 mg od I.V for 14 days Ruxolitinib-5 mg B.I.D per to 28 days. |          |
|                           |                  |                     |          |
| NCT04334044               | • Single group assignment | • Ruxolitinib- 5 mg twice a day orally | • Recovery from pneumonia |
|                           | • Open-label     |                     |          |
|                           | • Interventional |                     |          |
|                           | • n = 20         |                     |          |
| NCT04362137               | • Randomized     | • Ruxolitinib       | • Patients with respiratory failure, require intensive care unit (ICU) |
|                           | • Double-blind   | Ruxolitinib- twice daily 5 mg (B.I.D) for 14–28 days. | • The proportion of dead patients |
|                           | • Placebo-controlled |                     |          |
|                           | • Multicentered  |                     |          |
|                           | • Interventional |                     |          |
|                           | • n = 402        | Placebo             |          |
| NCT04331665               | • Single arm     | • Placebo for 14–28 days. | • The proportion of ill patients with COVID-19 pneumonia |
|                           | • Open-label     | Ruxolitinib          | • The number of adverse events. |
|                           | • Interventional | Ruxolitinib-10 mg, 2x/day, for 14 days. Following this, 5 mg, 2x/day for 2 days, and then 5 mg, 1x/day for a day. |          |
|                           | • n = 64         |                     |          |

(Continued)
| Study Parameters | Intervention groups | Clinical Trial Identifier | Cohort | Non-randomized assignments | n | Non-profit | n | Study | Parameters | Study | Parameters | Study | Parameters | Study | Parameters | Study | Parameters |
|------------------|---------------------|---------------------------|--------|---------------------------|---|-----------|---|-------|-------------|-------|-------------|-------|-------------|-------|-------------|-------|-------------|
|                  | Ruxolitinib         | NCT04361903               | Cohort | Single-arm                | 13 | Retrospective | Non-profit | n = 13 | Cohort | Single-arm | Non-randomized | n = 20 | Interventional | n = 20 | Parallel assignment | n = 4 | Interventional | n = 15 | Interventional | n = 20 | Interventional |
|                  |                     |                           |        |                           |    | Monocentric |            |       |        |            |                   |        |             |            |               |        |             |            |               |        |             |
|                  |                     |                           |        |                           |    | Non-profit |            |       |        |            |                   |        |             |            |               |        |             |            |               |        |             |
|                  |                     |                           |        |                           |    | Observational |            |       |        |            |                   |        |             |            |               |        |             |            |               |        |             |
|                  | Ruxolitinib         | NCT04338958               | Open-label | Single-arm | 200 | Non-randomized | Interventional | n = 200 | Open-label | Single-arm | Randomized | n = 216 | Parallel assignment | n = 20 | Interventional | n = 15 | Interventional | n = 20 | Interventional |
|                  |                     |                           |        |                           |    | Interventional |             |       |        |            |                   |        |             |            |               |        |             |            |               |        |             |
|                  | Ruxolitinib         | NCT04424056               | Observation | Non-randomized | n = 206 | Interv | n = 206 | Observation | Non-randomized | n = 15 | Interventional | n = 15 | Parallel assignment | n = 20 | Interventional | n = 20 | Interventional | n = 20 | Interventional |
|                  |                     |                           |        |                           |    | Standard of Care |             |       |        |            |                   |        |             |            |               |        |             |            |               |        |             |
|                  | Ruxolitinib         | NCT04331665               | Open-label | Single-arm | 64 | Open-label | Single-arm | n = 64 | Open-label | Single-arm | Randomized | n = 15 | Parallel assignment | n = 15 | Randomized | n = 20 | Randomized | n = 20 | Randomized |
|                  |                     |                           |        |                           |    | Interventional |             |       |        |            |                   |        |             |            |               |        |             |            |               |        |             |
|                  | Ruxolitinib         | NCT04374149               | Observation | Non-randomized | n = 20 | Sequential assignment | Open-label | n = 20 | Observation | Non-randomized | Sequential assignment | n = 20 | Interventional | n = 20 | Interventional | n = 20 | Interventional |
|                  |                     |                           |        |                           |    | Sequential assignment |             |       |        |            |                   |        |             |            |               |        |             |            |               |        |             |
|                  | Ruxolitinib         | NCT04359290               | Observation | Single-group assignment | 15 | Open-label | Single-group assignment | n = 15 | Open-label | Single-group assignment | Randomized | Double-blind | n = 20 | Parallel assignment | n = 20 | Parallel assignment | n = 20 | Parallel assignment | n = 20 | Parallel assignment |
|                  |                     |                           |        |                           |    | Interventional |             |       |        |            |                   |        |             |            |               |        |             |            |               |        |             |

- Patients avoiding mechanically-assisted ventilation in ARDS occurring in COVID-19 patients.
- Patients obtaining a 25% reduction in hyper-inflammation score on day 7.
- The number of days without mechanical ventilation.
- Patients with ≥ 33% decrease in cytokine load in one-third or more participants.
- Overall survival of COVID-19 patients.
- Death, ICU admission, mechanical ventilation at day 14.
- Oral placebo for 14 days, BID.
Table 2. (Continued).

| Clinical Trials Identifier | Study Parameters | Intervention groups | Outcomes |
|----------------------------|------------------|---------------------|----------|
| NCT04403243               | • Randomized     | • Colchicine        | • Measurement of respiratory rate, body temperature, ventilation, CRP, D-dimer levels |
|                           | • Open-label     | Colchicine- oral 0.5 mg 2x/day (0–3 days) followed by 0.5 mg 1x/day oral if weight is less than 86 kg or 0.5 mg 2x/day oral if weight is more than 85 kg for up to 7 days. |
|                           | • Parallel assignment |                        |          |
|                           | • Intentional    | Ruxolitinib         |          |
|                           | • n = 70         | Ruxolitinib- 5 mg 2/d orally for ten days |
|                           |                  | Secukinumab         |          |
|                           |                  | Secukinumab- 300 mg s.c first dose and 150 mg 2/d s.c for ten days |
| NCT04348695               | • Randomized     | • Ruxolitinib and Simvastatin | • Cases developing severe respiratory failure |
|                           | • Open-label     | Ruxolitinib- Every 12 h, 5 mg orally (0–7 days), later increased to 10 mg/12 h for 14 days. |
|                           | • Parallel assignment |                        |          |
|                           | • Intentional    | Simvastatin- Orally 40 mg/24 h for 14 days. |
|                           | • n = 94         | Standard therapy    |          |
| NCT04351503               | • Retrospective  | • SARS-CoV-2 infected patients | • Identification of factors associated with infection, hospitalization, and requirement of ICU treatment. |
|                           | • Observational | Study A: Data on clinical outcomes and features of SARS-CoV-2 infection. Study B: Data on epidemiological surveillance to describe the epidemiology of the SARS-CoV-2. |
|                           | • n = 10,000     | Study C: Data on viral evolution. |
|                           |                  | • Non-SARS-CoV-2 infected patients |
|                           |                  | Study A: Data on clinical outcomes and features of SARS-CoV-2 infection. |
| NCT04278404               | • Prospective    | • Collection of body fluids of children to compare outcomes with the standard of care | • Clearance |
|                           | • Observational |                        | • Half-life |
|                           | • n = 500        |                        | • Volume of distribution |
|                           |                  |                        | • Elimination rate constant |
|                           |                  |                        | • Half-life |
### Table 3. Summary of active clinical trials employing Baricitinib in COVID-19 patients.

| Clinical Trials Identifier | Study Parameters | Intervention groups | Outcomes |
|----------------------------|-------------------|---------------------|----------|
| NCT04340232 | Single-arm | Baricitinib 2 mg- once daily orally for 14 days | Cumulative events affecting daily living, clinical status, and life-threatening events. |
| | Open-label | | |
| | Single site | | |
| | Intervenotional | | |
| | n = 80 | | |
| NCT04421027 | Randomized | Baricitinib 4mg orally | Cases needing: Non-invasive ventilation |
| | Double-Blind | Placebo-control | High-Flow Oxygen |
| | Placebo-Controlled, | | Invasive Mechanical Ventilation |
| | Parallel assignment | | |
| | Intervenotional | | |
| | n = 600 | | |
| NCT04373044 | Randomized | Placebo and Hydroxychloroquine | Patients needing invasive mechanical ventilation |
| | Assignment | Placebo p.o daily, and standard of care hydroxychloroquine PO TID for 14 days. | Dead patients |
| | Intervenotional | Baricitinib and Hydroxychloroquine | |
| | n = 144 | Baricitinib p.o + Hydroxychloroquine p.o for 14 days. | |
| NCT04393051 | Randomized | Baricitinib | The decrease in patients requiring invasive ventilation |
| | Multicentered | Baricitinib- orally 4 mg or 2 mg/day (1–14 days) for 14 days. | |
| | Open-label | | |
| | Parallel Assignment | | |
| | Intervenotional | | Standard therapy |
| | n = 126 | | |
| NCT04362943 | Retrospective | Baricitinib or Anakinra | Mortality rate. |
| | Observational | | |
| | n = 576 | | |
| NCT04390464 | Randomized | Baricitinib + Standard of care (SOC) | The number of days taken for death, mechanical ventilation, renal failure. |
| | Parallel assignment | Baricitinib- orally 4 mg 1/day for 14 days with SOC. | |
| | Open-label | Ravulizumab + SOC | |
| | Intervenotional | Ravulizumab on day 1 as per patient weight with SOC. | |
| | n = 1167 | | |
| NCT04401579 | Randomized | Remdesivir + Baricitinib | Time to recovery |
| | Double-blinded | Remdesivir –200 mg IV (Day 1), following maintenance dose of 100 mg 1/d till 10 days and Baricitinib 2 × 2 mg tablets for 14 days via the oral route. | |
| | Multicentre | Remdesivir + Baricitinib | |
| | Adaptive | Remdesivir –200 mg IV (Day 1), following maintenance dose of 100 mg 1/d till 10 days and Baricitinib placebo 2 × 2 mg tablets for 14 days via the oral route. | |
| | Intervenotional | | |
| | n = 1034 | | |
| NCT04346147 | Randomized | Hydroxychloroquine and Lopinavir/Ritonavir | Time to clinical improvement |
| | Open-label | Hydroxychloroquine 200 mg/12 hours and Lopinavir/Ritonavir 200/50 mg/12 hours | |
| | Parallel assignment | Hydroxychloroquine and Imatinib | |
| | Intervenotional | | Hydroxychloroquine tablet 200 mg/12 hours and Imatinib tablet 400 mg/24 hours. |
| | n = 165 | | Hydroxychloroquine and Baricitinib |
| | | | A single tablet of Hydroxychloroquine 200 mg/12 hours and Baricitinib 4 mg/24 hours. |

(Continued)
Table 3. (Continued).

| Clinical Trials Identifier | Study Parameters | Intervention groups | Outcomes |
|----------------------------|------------------|---------------------|----------|
| NCT04321993                | • Non-Randomized  | • Baricitinib       | • Clinical status of patients at day 15. |
|                            | • Parallel assignment | Baricitinib-2 mg orally for 0–10 days. |          |
|                            | • Open-label      |                      |          |
|                            | • Interventional  |                      |          |
|                            | • n = 800         |                      |          |
| NCT04320277                | • Non-Randomized  | • Baricitinib and Lopinavir/Ritonavir |          |
|                            | • Cross-over assignment | Baricitinib-4 mg/day orally + ritonavir for 2 weeks. |          |
|                            | • Open-label      |                      |          |
|                            | • Interventional  |                      |          |
|                            | • n = 200         |                      |          |
| NCT04399798                | • Single group assignment | Baricitinib-4 mg/day |          |
|                            | • Open-label      | for 7 days.          |          |
|                            | • Interventional  |                      |          |
|                            | • n = 13          |                      |          |
| NCT04366206                | Prospective Cohort | Patients are either | • Composite of death and mechanical ventilation. |
|                            | • Multicentred    | subjected to treatment or the |          |
|                            | • Double-blind    | identified risk factor.  |          |
|                            | • Placebo-controlled | Patients are not exposed |          |
|                            | • Interventional  | to treatment or risk factor. |          |
|                            | • n = 143         |                      |          |
| NCT04365764                | Cross-sectional   | Patients who are given treatment. |         |
|                            | • Case control    | Patients who are not given treatment. |          |
|                            | • Observational   |                      |          |
|                            | • n = 400         |                      |          |

Table 4. Summary of active clinical trials employing Tofacitinib in COVID-19 patients.

| Clinical Trials Identifier | Study Parameters | Intervention groups | Outcomes |
|----------------------------|------------------|---------------------|----------|
| NCT04415151                | • Randomized     | • Tofacitinib       | • Improvement in clinical results of COVID-19 cases. |
|                            | • Parallel assignment | Tofacitinib- orally 10 mg (B.I.D) followed by 5 mg (B.I.D) for 0–14 days. |          |
|                            | • Interventional  |                      |          |
|                            | • n = 60          |                      |          |
| NCT04469114                | • Randomized     | • Tofacitinib       | • Death or respiratory failure at day 28. |
|                            | • Multicentred    |                      |          |
|                            | • Double-blind    | Tofacitinib-10 mg orally 2x/day for 14 days or up to discharge from hospital |          |
|                            | • Placebo-controlled | Placebo |          |
|                            | • Interventional  |                      |          |
|                            | • n = 260         |                      |          |
| NCT04390061                | • Randomized     | • Tofacitinib + Hydroxychloroquine | • Patients maintaining PaO2/FIO2 > 150 via mechanical ventilation |
|                            | • Multicentred    | Tofacitinib-10 mg cp 2/day + Hydroxychloroquine-200 mg cp 3/day both for 0–14 days. |          |
|                            | • Open-label      | Hydroxychloroquine |          |
|                            | • Interventional  | Hydroxychloroquine-200 mg cp 3/day both for 0–14 days. |          |
|                            | • n = 116         |                      |          |
| NCT04332042                | Prospective cohort study | Tofacitinib | • Patients requiring the use of mechanical ventilation for PaO2/FIO2 > 150 |
|                            | • Single group assignment | Tofacitinib-10 mg 2/day for 0–14 days. |          |
|                            | • Open-label      |                      |          |
|                            | • Interventional  |                      |          |
|                            | • n = 50          |                      |          |
Table 5. Active clinical trial employing Pacritinib in COVID-19 patients.

| Clinical Trials Identifier | Study Parameters | Intervention groups | Outcomes |
|----------------------------|------------------|---------------------|----------|
| NCT04415151                | Randomized       | Pacritinib + SOC    | Patients progressing to Intermittent Mandatory Ventilation (IMV) and/or Extracorporeal membrane oxygenation (ECMO) |
|                            | Double-blinded   | Pacritinib-400 mg 1/day (QD) at day1, then 200 mg 2x/day (BID) from Day 2–14 + SOC. | Death of patients along 28 days post-randomization. |
|                            | Placebo-control  |                     |          |
|                            | Multicentered    |                     |          |
|                            | Interventional   |                     |          |
|                            | n = 358          |                     |          |
|                            |                   | Placebo + Standard of care |          |

were interventional and included Tofacitinib as the sole drug in the therapeutic regimen except (NCT04390061) where hydroxychloroquine was compared as shown in Table 4.

The single regimen study of Pacritinib (NCT04404361) is undergoing phase III trials. It is a randomization study that is designed in a double-blinded setup, having a placebo-control, and is carried out at multiple sites. Its main aim is to ascertain the effectiveness and safety of Pacritinib in COVID-19 either having or not having cancer as elaborated in Table 5.

10. Conclusion

Inflammation majorly contributes to the worsening of COVID-19. The JAK/STAT pathway is involved in the cytokine and chemokine signaling that regulates inflammation in organisms. This is attributed to the ability of cytokines receptors to phosphorylate JAK and then STAT that ultimately bind to the DNA in the nucleus translating for inflammatory mediators.

With the onset of SARS-CoV-2 infection, its nsp3 facilitates STAT phosphorylation causing the unraveling of the inflammatory cascade leaving markers like CRP, ESR, PCT, SAA, serum ferritin, and NLR that determine disease severity. Thus, it becomes essential to introduce the JAK/STAT inhibitors that act via SOCS, PIAS, and PTP proteins that seem to be operative in counteracting the inflammatory actions of the SARS-CoV-2. Their use has been associated with adverse reactions like GI toxicity, diarrhea, dizziness, nasopharyngitis, elevation in ALT, AST levels, angioedema, pulmonary embolism, yet WHO, NIH, ICMR, NIAID have supported several clinical trials that are in progress to ascertain its safety and efficacy in COVID-19 patients.

The JAK/STAT signaling inhibition looks to be a promising approach to reduce inflammation in COVID-19 patients yet falls short of concrete conclusions due to a lack of understanding of mechanism occurring at molecular levels thus warranting further studies.

Acknowledgments

We thank the Manipal Academy of Higher Education for providing Dr. TMA Pai scholarship to Mr. Sairaj Sarker.

Funding

This work did not receive any specific funding.

Declaration of financial/other relationships

The contents of the paper and the opinions expressed within are those of the authors, and it was the decision of the authors to submit the manuscript for publication.

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Disclosure statement

No potential conflict of interest was reported by the authors.

ORCID

Sairaj Sarker http://orcid.org/0000-0002-4213-2664
Antriya Annie Tom http://orcid.org/0000-0002-0699-1955
Roshitha Ann Shaji http://orcid.org/0000-0002-2891-1784
Aaja Alosious http://orcid.org/0000-0001-8929-4129
Mariya Luvis http://orcid.org/0000-0003-2197-9097
Madhavan Nampoothiri http://orcid.org/0000-0003-2218-2004

References

1. Seif F, Aazami H, Khoshmirsa M, et al. JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol. 2020;181:467–475.
2. Banerjee S, Biehl A, Gadina M, et al. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521–546.
3. Billing U, Jetka T, Nortmann L, et al. Robustness and information transfer within IL-6-induced JAK/STAT signalling. Commun Biol. 2019;2:227.
4. Zhang J-M, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45:27–37.
5. Ragab D, Eldin SH, Taemah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.
6. Lacy P, Stow JL. Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood. 2011;118:9–18.
7. Wang J, Jiang M, Chen X, et al. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108:17–41.
8. Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9:7204–7218.
9. Hojojo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40. DOI:10.1186/s41232-020-00146-3.
10. Thevarajan I, Buisin KL, Cowie BC. Clinical presentation and management of COVID-19. Med J Aust. 2020;213:134–139.
11. Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020;55:91–98.

12. Bhaskar S, Sinha A, Banach M, et al. Cytokine storm in COVID-19—immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol. 2020;11:1648.

13. Satarker S, Nampoothiri M. Structural proteins in severe acute respiratory syndrome Coronavirus-2. Arch Med Res. 2020;51:482–491.

14. Castelli V, Cimini A, Ferri C. Cytokine storm in COVID-19: "when you come out of the storm, you won’t be the same person who walked in". Front Immunol. 2020;11:2132.

15. Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis. 2020;96:467–474.

16. Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. Natl. Sci. Rev. 2020;7:998-1002.

17. Kong M, Zhang H, Cao X, et al. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect. 2020;148:1–6.

18. Yan L, Li F, Wang X, et al. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: a retrospective cross-sectional study. J Med Virol. 2020;92:2573–2581.

19. Pimentel GD, Dela Vega MCM, Laviano A. High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients. Clin Nutr ESPEN. 2020;84:106504.

20. Feng X, Li S, Sun Q, et al. Immune-inflammatory parameters in COVID-19 cases: a systematic review and meta-analysis. Front Med. 2020;7:301.

21. Satarker S, Nampoothiri M. Involvement of the nervous system in COVID-19: the bell should toll in the brain. Life Sci. 2020;262:118568.

22. Abdin SM, Elgendy SM, Alyammahi SK, et al. Tackling the cytokine storm in COVID-19: challenges and hopes. Life Sci. 2020;257:118054.

23. Domingo P, Mur I, Pomar V, et al. The four horsemen of a viral Apocalypse: the pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine. 2020;58:102887.

24. Rockb B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020;368:1012–1015.

25. Kao KC, Hu HC, Chang CH, et al. Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy. Crit Care. 2015;19:228.

26. Tian S, Hu W, Niu L, et al. Pulmonary pathology of early-phase 2019 Novel Coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700–704.

27. Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020. DOI:10.1038/s41379-020-00661-1.

28. Jeffers SA, Tussell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci. 2004;101:15748–15753.

29. Chen Y, Chan VSF, Zheng B, et al. A novel subset of putative stem/progenitor CD34+ Oct-4+ cells is the major target for SARS coronavirus in human lung. J Exp Med. 2007;204:2529–2536.

30. Yu F, Jia R, Tang Y, et al. SARS-CoV-2 infection and stem cells: interaction and intervention. Stem Cell Res. 2020;46:101859.

31. Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587:657–662.

32. Mondal R, Lahiri D, Deb S, et al. COVID-19: are we dealing with a multisystem vasculopathy in disguise of a viral infection? J Thromb Thrombolysis. 2020;50:567–579.

33. Emameh RZ, Nosrati H, Eftekhar M, et al. Expansion of single cell transcriptomics data of SARS-CoV infection in human bronchial epithelial cells to COVID-19. Biol Proced Online. 2020;22:16.

34. Gao Y-M, Xu G, Wang B, et al. Cytokine storm syndrome in coronavirus disease 2019: a narrative review. J Intern Med. 2020. DOI:10.1111/joim.13144.

35. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016–1035.

36. Jafarzadeh A, Chauhan P, Saha B, et al. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020;257:118102.

37. McClay PB, Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81:813–821.

38. Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583:830–833.

39. Jiang R-D, Liu M-Q, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice reveals human angiotensin-converting enzyme 2. Cell. 2020;182:50–58.

40. Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21:1327-1335.

41. Park MD. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol. 2020;20:351.

42. Thomas G, Frederick E, Hausburg M, et al. The novel immunomodulatory biologic LMWFS5A for pharmacological attenuation of the “cytokine storm” in COVID-19 patients: a hypothesis. Patient Saf Surg. 2020;14:21.

43. Rael LT, Bar-Or R, Banton KL, et al. The anti-inflammatory effect of LMWFS5A and N-acetyl kynurenine on macrophages: involvement of aryl hydrocarbon receptor in mechanism of action. Biochem Biophys Reports. 2018;15:61–67.

44. Market M, Angka L, Martel AB, et al. Flattening the COVID-19 curve with natural killer cell based immunotherapies. Front Immunol. 2020;11:1512.

45. Guillón A, Hiemstra PS, Si-Tahar M. Pulmonary immune responses against SARS-CoV-2 infection: harmful or not? Intensive Care Med. 2020;46:1897–1900.

46. Popov D. Treatment of Covid-19 infection. A rationale for current and future pharmacological approach. Ec Pulmonol Respir Med. 2020;9:38–58.

47. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;1209:eabc8511.

48. Iqbal H. The importance of cell-mediated immunity in COVID-19 – an open-end. Med Hypotheses. 2020;143:110152.

49. Polycarpou A, Howard M, Farrar CA, et al. Rationale for targeting complement in COVID-19. EMBO Mol Med. 2020;12:e12642.

50. Kuchipudi SV. The complex role of STAT3 in viral infections. J Immunol Res. 2015;2015:272359.

51. Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020;6:31.

52. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. 2010;142:847–856.

53. Pérez GTL, Sandoval M de LPR, Altamiranoew MST. Evaluation of immune response, comorbidities and immunomodulation in SARS-CoV2 pandemic. EC Paediatr. 2020;9:70–90.

54. Yang D, Chu H, Hou Y, et al. Attenuated interferon and proinflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020;222:734–745.

55. Gotthardt D, Trifinopoulos J, Sexl V, et al. JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation. Front Immunol. 2019;10:2590.
56. O’Shea JJ, Plenge R. JAKs and STATs in immunoregulation and immune-mediated disease. Immunity. 2013;36:542–550.
57. Meletiadis J, Tsiodras S, Tsimpogi P. Interleukin-6 blocking vs. JAK-STAT inhibition for prevention of lung injury in patients with COVID-19. Infect Dis Ther. 2020;9:707–713.
58. Bouwman W, Verhaegh W, Holtzer L, et al. Measurement of cellular immune response to viral infection and vaccination. Front Immunol. 2020;11:1–13.
59. Rojas P, Sarmiento M. JAK/STAT pathway inhibition may be a promising therapy for COVID-19-related hyperinflammation in hematologic patients. Acta Haematol. 2020; [cited 2020 Nov 18]:1–5. DOI:10.1159/000510179
60. Claverie J-M. A putative role of de-mono-ADP-ribosylation of STAT1 by the SARS-CoV-2 Nsp3 protein in the cytokine storm syndrome of COVID-19. Viruses. 2020;12:646.
61. Khan SA, Zia K, Ashraf S, et al. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J Biomol Struct Dyn. 2020; [cited 2020 May 29]:1–10. DOI:10.1080/07391102.2020.1751298
62. Prasad S, Pothar V, Cherian S, et al. Transmission electron microscopy imaging of SARS-CoV-2. Indian J Med Res. 2020;151:241–243.
63. Satarker S, Ahuja T, Banerjee M, et al. Hydroxychloroquine in COVID-19: potential mechanism of action against SARS-CoV-2. Curr Pharmacol Rep. 2020;6:203–211.
64. Xu J, Lazartigues E. Expression of ACE2 in human neurons supports the neuro-invasive potential of COVID-19 virus. Cell Mol Neurobiol. 2020; [cited 2020 Aug 13]:1–5. DOI:10.1007/s10571-020-00915-1
65. Volloco C, Rollo E, RomoZZi M, et al. Focal status epilepticus as unique clinical feature of COVID-19: a case report. Seizure Eur J Epilepsy. 2020; 78:109–112.
66. Catanzaro M, Fagiani F, Racchi M, et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5:84.
67. Wang N, Shang J, Jiang S, et al. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298.
68. Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7:11.
69. Klemm T, Ebert G, CallaZZ DJ, et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. Embo J. 2020;39:1–17.
70. Silva-lópeZZ RE. The main protease of SARS-CoV-2 as therapeutic target to development specific drugs to treat COVID-19. J Appl Biotechnol Bioeng. 2020;7:185–189.
71. StanciuZZ F, Papadakis G, KteniadiZZs S, et al. A dissection of SARS-CoV2 with clinical implications (Review). Int J Mol Med. 2020;46:498–509.
72. Xia H, Cao Z, Xie X, et al. Evasion of Type I Interferon by SARS-CoV-2. Cell Rep. 2020;33:108234.
73. Astuti JY. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr Clin Res Rev. 2020;14:407–412.
74. Wu Y, Ma L, Zhuang Z, et al. Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling. Vol. S. Signal Transduct Target Ther. 2020;5:221.
75. Prescott L. SARS-CoV-2 3CLpro whole human proteome cleavage prediction and enrichment/depletion analysis. bioRxiv Prepr. 2020; [cited 2020 Nov 17]. DOI:10.1101/2020.08.24.265645.
76. Mu J, Fang Y, Yang Q, et al. SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov. 2020;6:65.
77. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355–362.
78. Alhammad YMO, Fehr AR. The viral macrodomain counters host antiviral ADP-ribosylation. Viruses. 2020;12:384.
79. Scarro G, Pietropaolo G, Di Censo C, et al. Transcriptional, epigenetic and pharmacological control of JAK/STAT pathway in NK cells. Front Immunol. 2019;10:2456.
80. Hong Y, Xin C, Zheng H, et al. miR-365a-3p regulates ADAM10-JAK-STAT signaling to suppress the growth and metastasis of colorectal cancer cells. J Cancer. 2020;11:3634–3644.
81. Alunno A, Padjen I, Fanourakis A, et al. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells. 2019;8:898.
82. Hammárén HM, Virtanen AT, Raiiola J, et al. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118:48–63.
83. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signaling pathway. Semin Cell Dev Biol. 2008;19:414–422.
84. Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel). 2019;11:2002.
85. BousioK E, Montazeri Aliabadi H. “Do We Know Jack” about JAK? A closer look at JAK/STAT signaling pathway. Front Oncol. 2018;8:287.
86. Luo W, Li Y-X, Jiang L-J, et al. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020;41:531–543.
87. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53:368–370.
88. Bettelli E, Korn T, Oukka M, et al. Induction and effector functions of TH17 cells. Nature. 2008;453:1051–1057.
89. von Essen M, Sandergaard H, Petersen E, et al. IL-6, IL-12, and IL-23 STAT-pathway genetic risk and responsiveness of lymphocytes in patients with multiple sclerosis. Cells. 2019;8:285.
90. Duncan SA, Baganzini DR, Sahu R, et al. SOCS proteins as regulators of inflammatory responses induced by bacterial infections: a review. Front Microbiol. 2017;8:2431.
91. Liu NP, Laktyushin A, Lucet IS, et al. The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun. 2018;9:1558.
92. Niu G-J, Xu J-D, Yuan W-J, et al. Protein inhibitor of activated STAT (PIAS) negatively regulates the JAK/STAT pathway by inhibiting STAT phosphorylation and translocation. Front Immunol. 2018;9:2392.
93. Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 2006;16:196–202.
94. Nakahira M, Tanaka T, Robson BE, et al. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity. 2007;26:163–176.
95. Nian Q, Berthelet J, Zhang W, et al. T-cell protein tyrosine phosphatase is irreversibly inhibited by etoposide-quinone, a reactive metabolite of the chemotherapy drug etoposide. Mol Pharmacol. 2019;96:297–306.
96. Pike KA, Hutchins AP, Vinette V, et al. Protein tyrosine phosphatase 1B is a regulator of the interleukin-10-induced transcriptional program in macrophages. Sci Signal. 2014;7:ra43.
97. La Rosée F, Bremer HC, Gehrke I, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34:1805–1815.
98. Verstovsek S. Ruxolitinib: an oral janus kinase 1 and janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med. 2013;125:128–135.
99. Capochiani E, Frediani B, Lervasi G, et al. Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. analysis of data collection from RESPIRE protocol. Front Med. 2020;7:466.
100. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146:137–146.e3.
101. Zhang X, Zhang Y, Qiao W, et al. Baricitinib, a drug with potential effect to prevent SARS-CoV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020;86:106749.
102. Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81:318–356.
103. Tang JW, Young S, May S, et al. Comparing hospitalised, community and staff COVID-19 infection rates during the early phase of the evolving COVID-19 epidemic. J Infect. 2020;81:647–679.

104. Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in severe COVID-19 patients. J Clin Invest. 2020. DOI:10.1172/JCI141772.

105. Mehta P, Ciurtin C, Scully M, et al. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. Eur Respir J. 2020;56:2001919.

106. Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42:759–773.

107. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 2013;12:611–629.

108. Lau Y-T, Ramaiyer M, Johnson D, et al. Targeting STAT3 in cancer with nucleotide therapeutics. Cancers (Basel). 2019;11:1681.

109. Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24:422.

110. Gaspari V, Zengarini C, Greco S, et al. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports. Int J Antimicrob Agents. 2020;56:106023.

111. Alberio L, Blum S, Martins F. Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. J Blood Med. 2016;7:205–215.

112. Jorgensen SCJ, Tse CLY, Burry L, et al. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacother J Hum Pharmacol Drug Ther. 2020;40:843–856.

113. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology. 2019;58:i34–i42.

114. World Health Organization (WHO). WHO Coronavirus disease (COVID-19) dashboard. [cited 2020 Sept 03]. Available from: https://covid19.who.int/.

115. Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–544.

116. World Health Organization (WHO). “Solidarity” clinical trial for COVID-19 treatments, 2020. [cited 2020 Sept 03]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.

117. Mahalmani VM, Mahendru D, Semwal A, et al. COVID-19 pandemic: a review based on current evidence. Indian J Pharmacol. 2020;52:117–129.

118. Cherian SS, Agrawal M, Basu A, et al. Perspectives for repurposing drugs for the coronavirus disease 2019. Indian J Med Res. 2020;151:160–171.